tradingkey.logo
搜尋

Edwards Lifesciences Corp

EW
添加自選
89.540USD
+5.720+6.82%
收盤 07-23 16:00美東報價延遲15分鐘
51.66B總市值
47.55本益比TTM

關於 Edwards Lifesciences Corp 公司

Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

Edwards Lifesciences Corp簡介

公司代碼EW
公司名稱Edwards Lifesciences Corp
上市日期Mar 27, 2000
CEOZovighian (Bernard J)
員工數量15800
證券類型Ordinary Share
年結日Mar 27
公司地址One Edwards Way
城市IRVINE
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家United States of America
郵編92614
電話19492502500
網址https://www.edwards.com
公司代碼EW
上市日期Mar 27, 2000
CEOZovighian (Bernard J)

Edwards Lifesciences Corp公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
284.40K
+2.48%
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
79.69K
+5.41%
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
39.29K
-0.96%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
30.12K
+59.32%
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
22.62K
+53.60%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.56K
+58.48%
Mr. Donald E. Bobo, Jr.
Mr. Donald E. Bobo, Jr.
Corporate Vice President - Strategy and Corporate Development
Corporate Vice President - Strategy and Corporate Development
--
--
Mr. Nicholas J. (Nick) Valeriani
Mr. Nicholas J. (Nick) Valeriani
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Kieran T. Gallahue
Mr. Kieran T. Gallahue
Independent Director
Independent Director
--
--
Ms. Leslie S. Heisz
Ms. Leslie S. Heisz
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
284.40K
+2.48%
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
79.69K
+5.41%
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
39.29K
-0.96%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
30.12K
+59.32%
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
22.62K
+53.60%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.56K
+58.48%

常見問題

Edwards Lifesciences Corp的前五大股東是誰?

Edwards Lifesciences Corp的前五大股東如下:Mr. Scott B. Ullem

有多少機構持有Edwards Lifesciences Corp(EW)的股份?

截至2026Q1,共有2620家機構持有Edwards Lifesciences Corp的股份,合計持有的股份價值約為539.60M,占公司總股份的93.71% 。與2025Q4相比,機構持股有所增加,增幅為-12944884.00。

哪個業務部門對Edwards Lifesciences Corp的收入貢獻最大?

在2026Q1,Transcatheter Aortic Valve Replacement業務部門對Edwards Lifesciences Corp的收入貢獻最大,創收4.49B,占總收入的73.96% 。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有